Amalgamated Bank cut its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART – Get Rating) by 3.5% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 50,283 shares of the life sciences company’s stock after selling 1,835 shares during the period. Amalgamated Bank’s holdings in Integra LifeSciences were worth $3,231,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in IART. Goldman Sachs Group Inc. grew its position in Integra LifeSciences by 73.7% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,482,718 shares of the life sciences company’s stock valued at $99,327,000 after purchasing an additional 629,202 shares in the last quarter. Alliancebernstein L.P. lifted its stake in Integra LifeSciences by 11.0% in the fourth quarter. Alliancebernstein L.P. now owns 2,329,360 shares of the life sciences company’s stock valued at $156,044,000 after acquiring an additional 231,383 shares during the last quarter. Leeward Investments LLC MA acquired a new stake in Integra LifeSciences in the first quarter valued at approximately $14,479,000. Arrowstreet Capital Limited Partnership lifted its stake in Integra LifeSciences by 266.9% in the first quarter. Arrowstreet Capital Limited Partnership now owns 234,446 shares of the life sciences company’s stock valued at $15,065,000 after acquiring an additional 170,543 shares during the last quarter. Finally, Cooke & Bieler LP lifted its stake in Integra LifeSciences by 6.4% in the first quarter. Cooke & Bieler LP now owns 2,529,419 shares of the life sciences company’s stock valued at $162,540,000 after acquiring an additional 152,293 shares during the last quarter. 87.33% of the stock is owned by hedge funds and other institutional investors.
In other Integra LifeSciences news, Director Raymond G. Murphy sold 8,000 shares of the firm’s stock in a transaction that occurred on Friday, August 5th. The shares were sold at an average price of $55.78, for a total transaction of $446,240.00. Following the sale, the director now directly owns 40,825 shares in the company, valued at approximately $2,277,218.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, EVP Lisa Evoli sold 1,165 shares of the business’s stock in a transaction dated Wednesday, August 10th. The shares were sold at an average price of $55.81, for a total value of $65,018.65. Following the completion of the sale, the executive vice president now owns 17,997 shares of the company’s stock, valued at $1,004,412.57. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Raymond G. Murphy sold 8,000 shares of the company’s stock in a transaction dated Friday, August 5th. The stock was sold at an average price of $55.78, for a total transaction of $446,240.00. Following the sale, the director now directly owns 40,825 shares of the company’s stock, valued at approximately $2,277,218.50. The disclosure for this sale can be found here. In the last quarter, insiders have sold 9,602 shares of company stock valued at $536,067. 4.20% of the stock is currently owned by insiders.
Integra LifeSciences Trading Down 1.1 %
Integra LifeSciences (NASDAQ:IART – Get Rating) last posted its quarterly earnings data on Wednesday, July 27th. The life sciences company reported $0.82 earnings per share for the quarter, beating the consensus estimate of $0.80 by $0.02. The firm had revenue of $397.82 million during the quarter, compared to analysts’ expectations of $394.54 million. Integra LifeSciences had a net margin of 10.61% and a return on equity of 16.72%. On average, equities research analysts forecast that Integra LifeSciences Holdings Co. will post 3.16 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of research firms have issued reports on IART. Piper Sandler reduced their target price on shares of Integra LifeSciences from $55.00 to $50.00 in a research note on Wednesday, August 24th. Morgan Stanley reduced their price objective on shares of Integra LifeSciences from $59.00 to $58.00 and set an “equal weight” rating for the company in a research note on Thursday, August 25th. TheStreet cut shares of Integra LifeSciences from a “b-” rating to a “c+” rating in a research note on Friday, July 8th. Finally, Truist Financial reduced their price objective on shares of Integra LifeSciences from $70.00 to $56.00 and set a “hold” rating for the company in a research note on Wednesday, July 20th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company. According to MarketBeat, Integra LifeSciences presently has a consensus rating of “Hold” and an average target price of $65.43.
About Integra LifeSciences
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services.
- Get a free copy of the StockNews.com research report on Integra LifeSciences (IART)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase’s Earnings Say About the Return to the Office?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.